Introduction {#Sec1}
============

Taxanes such as docetaxel and paclitaxel have been widely used for the treatment of various types of cancers, including breast, lung, gynecological and gastric cancers, as palliative chemotherapies. Since common adverse effects such as bone marrow and gastrointestinal toxicities have become manageable due to the development of granulocyte colony-stimulating factor (G-CSF) \[[@CR1], [@CR2]\] and 5-HT~3~ antagonists \[[@CR3], [@CR4]\], the adverse events related to cutaneous toxicities after taxane treatment have become more important. The important cutaneous toxicities due to taxane treatment include hand--foot skin syndrome and nail-related adverse events. Minisini et al. have reported that more than 40% of patients treated with taxanes developed nail toxicities \[[@CR5]\]. In our department, approximately 45% of patients receiving docetaxel treatment for 4 months or longer developed clinically significant nail toxicities (unpublished data). This is especially relevant for breast cancer patients, who received higher doses of taxanes than patients with other types of cancer: more than 60% of these patients showed clinically significant nail toxicities. Nail toxicities include pigmentation, onychitis, onycholysis, hemorrhage and tenderness in the nail bed. Although these adverse events are not life threatening, they do not recover in a short period of time and make it difficult to continue chemotherapy, resulting in negative consequences for the patient's prognosis.

Scottë et al. reported that applying Elasto-Gel frozen gloves (FG) reduced nail-related adverse events in patients receiving docetaxel at 75 mg/m^2^ alone or in combination chemotherapy \[[@CR6]\]. They used gloves frozen at −25 to −30°C, and 11% of patients dropped out of the study after experiencing discomfort due to cold intolerance. In our pilot trial, frozen gloves were also applied; however, some patients were not able to wear them for a predetermined period (90 min) due to discomfort (cold intolerance). Several studies have demonstrated the usefulness of the vasoconstrictor effect of cold stimulation on oral cavities (oral cryotherapy) and the scalp (scalp cooling system) \[[@CR7]--[@CR10]\]. For example Ridderheim et al. reported that maintaining a constant scalp temperature of +5°C prevented alopecia in patients treated with anthracyclines \[[@CR9]\]. In oral cryotherapy, it is very unlikely that oral cavity temperatures are maintained at 0°C or less \[[@CR10]\]. In addition, it may be impossible to use a −30°C freezer in some medical facilities; therefore, the temperature of −10° to −20°C which can be maintained by the freezer compartment of a household refrigerator may be ideal for routine clinical use. From our careful clinical observations of eight hospital staff volunteers, there were no differences in the duration of the cooling effect or in skin temperatures of the hands and fingers between gloves frozen at −25 to −30°C and −10 to −20°C. Some had redness and increased skin temperatures possibly due to reactive increase in blood flow in the hand wearing the glove frozen at −25 to −30°C. Furthermore, seven out of eight volunteers experienced discomfort due to cold intolerance only in the hand wearing the glove frozen at −25 to −30°C \[[@CR11]\].

Based on these results, we designed a study to compare the cooling effects in each individual patient between one control hand wearing a glove frozen for at least overnight at −25 to −30°C, for 90 min, and the other experimental hand wearing a glove frozen at −10 to −20°C. Considering the maximum blood concentration time (*T*~max~) of docetaxel (60 min after the initiation of dosing) \[[@CR12]\], the patients wore a single glove on the experimental side (the glove frozen at −10 to −20°C for 90 min) from 15 min after the initiation of docetaxel infusion to 15 min after the end of the infusion, in order to enable a single glove to cover the hand during the 60 min around the time point of maximum drug concentration.

In general, each patient currently requires four gloves in total daily (two for each hand), frozen for at least 3 h or overnight; however, if an alternative method is available using only two gloves in total daily (one for each hand) that are frozen for a shorter duration (90 min, the time required for the patient's blood test results to become available), it may be more practical for clinical use.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

Women eligible for this study were pathologically proven stage IV or recurrent breast cancer patients who were not candidates for curative surgery, between 20 and 69 years of age, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 with adequate organ functions, scheduled to receive docetaxel at 40 mg/m^2^ or more at least once a month and who had not received more than two doses of docetaxel on entry to the study. The criteria for exclusion included peripheral neuropathy, edema, Raynaud's symptoms or peripheral arterial ischemia which were graded 2 or higher, the presence of suspected metastasis in the bone, soft tissue or skin of the hands, the presence of pleural and pericardial effusion and ascites requiring drainage, and pre-existing nail toxicities which were scored as equal to or higher than 5 by protocol-defined scoring. All participants gave their written informed consent prior to their inclusion in this study.

Study design {#Sec4}
------------

In this self-controlled trial, we compared the efficacy and discomfort of FG (Elasto-Gel flexible gloves, 84400 APT Cedex, Akromed, France) prepared using different degrees of freezing. Patients enrolled onto this study were to receive docetaxel over 1 h after appropriate premedication such as dexamethasone. Some patients also received other chemotherapeutic agents in combination and/or zoledronic acid.

For each patient, three frozen gloves were prepared and used as follows. As standard protection (control), each patient wore an FG on the left hand which was prepared at −25 to −30°C at least overnight. These FG were worn on the left hand from 15 min before docetaxel administration, during the 1-h docetaxel infusion and until 15 min after the end of infusion, a total duration of 90 min. In order to maintain the low temperature, two gloves were used successively for 45 min each \[[@CR6]\]. On the right hand, each patient wore an FG prepared at −10 to −20°C for 90 min in the freezer compartment of a household refrigerator. This was used from 15 min after the start of docetaxel infusion until 15 min after the end of docetaxel infusion, a total of 60 min.

This study was approved by the Ethics Committee of Kyoto University Graduate School of Medicine (C-79) and conducted in accordance with the Ethical Guidelines for Clinical Studies by the Ministry of Health, Labour and Welfare, Japan (July 30, 2003, amended December 28, 2004) and the Helsinki Declaration (1964, amended in 1975, 1983, 1989, 1996, 2000 and 2004) of the World Medical Association. This study was registered to the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) managed by the National University Hospital Council of Japan and operated by the University of Tokyo Hospital (UMIN000000478).

Assessment {#Sec5}
----------

Nail toxicities and discomfort due to FG were assessed and graded by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) v3.0 before study entry and prior to every docetaxel administration in the Outpatient Oncology Unit. Nail toxicity was documented by photography and scored as follows. Grade 1 nail toxicity was given 1 point for each finger with a maximum of 5 points per hand. Grade 2 nail toxicity was given 5 points for each finger. Total points for each hand were recorded for docetaxel-induced nail toxicity (DNT).

Pharmacokinetics {#Sec6}
----------------

The pharmacokinetics of docetaxel was assessed within 1 month of enrollment. Blood samples were obtained prior to docetaxel infusion, immediately before the end of infusion and 10, 30, 60, 120 and 180 min after the end of infusion. Drug concentration was measured by high performance liquid chromatography with tandem mass spectrometry. Pharmacokinetic parameters were calculated with the software WinNonlin (Pharsight Co., Mountain View, CA) using the two-compartment model.

Statistical methodology {#Sec7}
-----------------------

The primary endpoint was DNT occurrence (more than a 2-point increase in nail toxicity scoring or any grade 2 toxicity) by 5 months. Secondary endpoints were as follows: any grade 2 or higher DNT occurrence by 5 months, docetaxel exposure \[cumulative dose and area under the blood concentration time curve (AUC)\] and time until DNT occurrence, discomfort from FG and a detailed description of specific DNT type.

It was estimated that the protective effect of FG on the control hand would be 90% (DNT 10%) at 5 months. The expected protection rate for the experimental side was 85%, and at least higher than 50% which is the protection rate without FG in the literature \[[@CR6]\]. It was estimated that analysis of 20 patients was required for a statistical power of 80%. To be eligible for FG efficacy evaluation, patients must have received more than five doses of docetaxel with a total of at least 160 mg/m^2^ or more, over 5 months or longer. A total enrollment of 25 patients was required for 80% of the enrolled patients to be evaluable for FG efficacy.

Results {#Sec8}
=======

Patients {#Sec9}
--------

The patients' demographic information is listed in Table [1](#Tab1){ref-type="table"}. The performance status (PS) of all enrolled patients (*n* = 23) was 0. About 80% of patients had received chemotherapy before enrollment, and most of these patients had received 5-fluoropyrimidines, such as UFT, S-1 and capecitabine. The next most common chemotherapy was cyclophosphamide in 70% of patients. Treatment information is summarized in Table [2](#Tab2){ref-type="table"}. The total cumulative dose of docetaxel and duration of administration was 560 mg/m^2^ (80--1430 mg/m^2^) and 9.0 months (0.6--24.3 months). Common concurrent cytotoxic and hormonal agents were cyclophosphamide and letrozole, respectively.Table 1Baseline clinical characteristics of all enrolled patients and those evaluable for frozen glove efficacyEnrolledEvaluable*n*%*n*%2316Age (years)Median5859Range40--6844--68\< 50417213≥ 50, \< 601148850≥ 60835638ComplicationsPeripheral neuropathy1416Edematous hand1416Raynaud's symptoms0000Peripheral arterial ischemia0000Smoking historyNever20871381Yes29213Unknown1416Performance status02310016100Prior chemotherapyNone522319Yes187813815-FluoropyrimidineUFT29213Doxifluridine939850Capecitabine835531S-1626425Fluorouracil29213AnthracyclineDoxorubicin1400Epirubicin417319TaxanePaclitaxel313319Vinca alkaloidVinorelbine1416AlkylatingCyclophosphamide16701169OthersMTX, MMC, CBDCA1416*MTX* methotrexate, *MMC* mitomycin C, *CBDCA* carboplatinTable 2Treatment and pharmacokinetic results of all enrolled patients and those evaluable for frozen glove efficacyEnrolledEvaluable*n*%*n*%2316Total docetaxel dose (mg/m^2^)Median560700Range80--1430340--1430Duration of docetaxel (months)Median9.011.5Range0.6--24.35.3--24.3\< 5.073000≥ 5.0167016100Combination chemotherapyNo31316Yes20871594Cytotoxic agentCyclophosphamide835638Capecitabine1400Epirubicin29213Hormonal agentAnastrozole1400Letrozole730531Exemestane313319MPA1400LH-RH analogue1400Molecular targetTrastuzumab522425Pharmacokinetics^a^AUC (mg\*h/L)Median1.731.76Range1.14--2.781.14--2.78Clearance (L/h)Median34.734.6Range22.8--52.223.0--51.9Clearance/BSA (L/h/m^2^)Median22.922.6Range14.5--35.614.5--35.6*C*~max~ (mg/mL)Median1.571.57Range0.94--2.340.94--2.34*V*~ss~ (L)Median12.512.6Range6.10--36.78.07--36.7^a^One patient whose pharmacokinetic analysis was not carried out correctly was excluded from enrolled and evaluable cohorts*AUC* area under the blood concentration time curve, *BSA* body surface area, *C*~*max*~ maximum concentration, *V*~*ss*~ volume in steady state, *MPA* medroxyprogesterone acetate, *LH-RH* luteinizing hormone releasing hormone

Efficacy of FG {#Sec10}
--------------

Sixteen patients met the pre-specified criteria for FG efficacy evaluation. The total cumulative dose of docetaxel and duration of administration was 700 (340--1430) mg/m^2^ and 11.5 (5.3--24.3) months within the population evaluated for FG efficacy (Table [2](#Tab2){ref-type="table"}). None of the 16 evaluable patients developed protocol-defined DNT before 5 months in either hand (Table [3](#Tab3){ref-type="table"}).Table 3Primary endpoint: protocol-defined docetaxel-induced nail toxicity (DNT) occurrence by 5 monthsNumberEventRate (%)95% Confidence intervalLeft handStandard: − 25 to −30°C16000--21%Right handExperimental: − 10 to −20°C16000--21%

After the initial evaluation period for the primary endpoint, two patients developed protocol-defined DNT at 7.2 and 7.3 months, respectively (Table [4](#Tab4){ref-type="table"}). The first patient (case \#4) developed grade 2 DNT (pain with nail pigmentation, and hemorrhage in the nail bed), and the cumulative docetaxel dose was 440 mg/m^2^ before development of DNT. Administration of docetaxel was terminated in this patient due to recurrence of DNT and progressive disease within a few months. The second patient (case \#10) developed nail tenderness with no other changes in the nails at a docetaxel dose of 480 mg/m^2^; however, this may not be related to docetaxel since this patient was able to receive further docetaxel doses of 880 mg/m^2^ (total 1360 mg/m^2^) without recurrence of DNT.Table 4Secondary endpoint: docetaxel exposure and duration before occurrence of protocol-defined DNTCase IDHandDuration until DNT occurrence (days)Docetaxel dose until DNT occurrence (mg/m^2^)Total docetaxel dose (mg/m^2^)Total duration(days)Type of event4Right222440640307Pigmentation, hemorrhage, pain10Right2204801360585Tenderness

Adverse events due to FG {#Sec11}
------------------------

Although none of the enrolled patients discontinued FG use due to intolerance, 100% (95% confidential interval 85--100%) and 52% (95% confidential interval 30--73%) of patients complained of discomfort at least once in their left (−25 to −30°C) and right (−10 to −20°C) hands, respectively, by 5 months of FG use (*p* \< 0.001 by McNemer test; Table [5](#Tab5){ref-type="table"}). When these results were analyzed by treatment cycle, the values were 92% (95% confidential interval 87--96%) and 15% (95% confidential interval 10--22%), respectively (*p* \< 0.001 by permutation test; Table [5](#Tab5){ref-type="table"}). Specific adverse events observed were pain (five patients = 22%, all events in the left hand), sensory neuropathy (one event in the right hand, one event in the left, each in a different patient) and arthritis (one patient in the right hand) (Table [6](#Tab6){ref-type="table"}).Table 5Adverse events due to use of frozen gloves (FG) in all enrolled patients: any discomfort due to FG at 5 months---by patient and by cycle**By patient*N*EventsRate (%)95% CI**Left hand Standard: −25 to −30°C232310085--100%Right hand Experimental: −10 to −20°C23125230--73% **By cycleCyclesEventsRate (%)95% CI**Left hand Standard: −25 to −30°C1461359287--96%Right hand Experimental: −10 to −15°C146221510--22%Table 6Other adverse events due to FGWorst grade*n* = 2301234≥ Grade 1 (%)Allergic reactionLeft hand (standard: −25 to −30°C)2300000Right hand (experimental: −10 to −15°C)2300000PainLeft hand (standard: −25 to −30°C)18500022Right hand (experimental: −10 to −15°C)2300000Sensory neuropathyLeft hand (standard: −25 to −30°C)2210004Right hand (experimental: −10 to −15°C)2210004ArthritisLeft hand (standard: −25 to −30°C)2300000Right hand (experimental: −10 to −15°C)2201004

Pharmacokinetic correlation {#Sec12}
---------------------------

The AUC (*n* = 22) of docetaxel (at 40 mg/m^2^) was 1.73 (1.14--2.78) mg\*h/L for all enrolled patients except one whose pharmacokinetic analysis was not carried out correctly (Table [2](#Tab2){ref-type="table"}). For patients evaluable for FG efficacy, the total cumulative dose of docetaxel (*n* = 16) was 700 (340--1430) mg/m^2^, and the AUC (*n* = 15) was 1.76 (1.14--2.78) mg\*h/L (Table [2](#Tab2){ref-type="table"}). Clearance (CL, *n* = 15) and CL adjusted by body surface area (*n* = 15) was 34.6 (23.0--51.9) L/h and 22.6 (14.5--35.6) L/h/m^2^ for those evaluable patients (Table [2](#Tab2){ref-type="table"}), which seems to be slightly lower than figures reported for the Western population \[[@CR13]\].

The AUC of case \#4, who developed DNT at day 222, was 1.71 mg\*h/L, which was comparable to the median (1.76 mg\*h/L) and mean (1.78 mg\*h/L) AUC. She had received only 440 mg/m^2^ of docetaxel before DNT occurrence. The AUC of case \#10 was 1.14 mg\*h/L. She had received 480 mg/m^2^ of docetaxel before DNT. On the other hand, none of the four patients whose AUC and total dose were both higher than the median (1.76 mg\*h/L and 560 mg/m^2^, respectively), out of the 15 patients evaluable for both FG efficacy and pharmacokinetics, developed protocol-defined DNT (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 1Total docetaxel dose before development of docetaxel-induced nail toxicity (DNT) or study closure was plotted for patients who met the evaluation criteria for frozen glove efficacy and pharmacokinetics. *Straight lines* and *broken lines* indicate mean and median values, respectively. *Open circles* represent data from patients who developed DNT and *closed circles* from patients without DNT. This figure was created using the Microsoft Office Powerpoint and JMP programFig. 2Area under the blood concentration time curve (AUC) for docetaxel administered at 40 mg/m^2^ was plotted for patients who met the evaluation criteria for frozen glove efficacy and pharmacokinetics. *Straight lines* and *broken lines* indicate mean and median values, respectively. *Open circles* represent data from patients who developed DNT and *closed circles* from patients without DNT. This figure was created using the Microsoft Office Powerpoint and JMP program. *AUC*~*inf*~ area under the blood concentration time curve extrapolated to infinity

Discussion {#Sec13}
==========

This study compared the effectiveness of FG prepared in two different ways and used on the right and left hand in the same patient. The standard application of FG was quite effective for DNT prevention but caused significant discomfort similar to that reported in the literature \[[@CR6]\]. On the other hand, the more convenient method including preparation for a shorter time at higher temperature as well as a shorter duration of application without FG replacement was not only as effective as the standard method but also caused less discomfort and was economically beneficial. The occurrence of DNT seems not to be predictable from simple docetaxel exposure.

This self-controlled study was neither blinded nor randomized, but comparison of the right and left hand in the same patient gives less bias relative to historical control comparisons. It is also unknown whether our findings can be applied to other taxane agents such as paclitaxel, including albumin-bound paclitaxel.

Another possible weakness of this study was the relatively lower starting dose of docetaxel (40 mg/m^2^) because the study protocol allowed for combination chemotherapy. In fact, 50% of patients received combinations such as cyclophosphamide and epirubicin. The study protocol also allowed for dose escalation depending on the pharmacokinetic results as well as clinical toxicity and efficacy according to the judgment of the treating physician. Median time to treatment failure in our study was 9.0 (0.6--24.2) months, and this is comparable to the time to treatment failure of modern chemotherapy regimens such as the docetaxel plus bevacizumab combination (8 months) \[[@CR14]\]. In the trial reported by Scottë et al. the cumulative dose of docetaxel was 810 (150--1275) mg/m^2^, and FG reduced the CTCAE G2 nail toxicity from 20% to zero \[[@CR6]\]. In a study of a Japanese patient population who received a 300-mg/m^2^ or higher dose of docetaxel, the incidence of CTCAE G2 nail toxicity was 14% (without protection in a historical control) versus 4.4% (FG protected) \[[@CR15]\]. The cumulative and lowest total docetaxel dose in our study is similar to those in the two studies cited previously. Furthermore, our study suggests that the degree of docetaxel exposure might not be an important causative factor for DNT occurrence.

FG are usually dried overnight after use and then frozen overnight or longer, which requires each institution to keep at least 80 FG for ten docetaxel-treated patients per day. The commercial cost of FG in Japan is ¥28, 000 per glove. It is also necessary to have a special freezer at −25 to −30°C to prepare FG. Since the cost of FG is not covered by health care insurance in Japan, a limited number of institutions use FG for patients who receive docetaxel. On the other hand, the method used in this study requires only two FG for each patient and requires only 90-min preparation, which means that 20 FG is enough to treat ten docetaxel-treated patients per day. It is also unnecessary to have a special freezer, since the freezer compartment of a household refrigerator is enough to maintain the temperature at −10 to −20°C. This method is therefore economically highly beneficial. In addition, the more convenient method used in this study is not only as effective as the standard method but causes less discomfort.
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